Rahul Khanna, MD
Neurology · West Burlington, IANPI 1548642473
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $33,075 of the $38,176 with a category attached, or 86.6%. Argenx US, Inc. accounts for 87.1% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2024 at $21,925 and has fallen 93.9% since, to $1,338 in 2025. Among neurology clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 247 payments — averaging $154.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Argenx US, Inc.$33K
- Livanova USA, Inc.$1K
- Pfizer$642
- AbbVie$502
- Harmony Biosciences LLC$445
- Biogen$323
- plus $2K from 25 others
What the payments were for
- Consulting fees$33,07587%
- Travel & lodging$6122%
- Food & beverage$4,36111%
- Education$1280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Argenx US, Inc. | 19 | $33,247 |
| Livanova USA, Inc. | 8 | $1,108 |
| Pfizer | 53 | $642 |
| AbbVie(2 entities) | 36 | $502 |
| Harmony Biosciences LLC | 38 | $445 |
| Biogen | 12 | $323 |
| SK Life Science, Inc. | 10 | $271 |
| Teva Pharmaceuticals USA, Inc. | 10 | $197 |
| Novartis | 10 | $192 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $155 |
| AstraZeneca | 1 | $118 |
| Lundbeck LLC | 6 | $115 |
| Lilly USA, LLC | 7 | $101 |
| E.r. Squibb & Sons, L.L.C. | 1 | $92 |
| Neurocrine Biosciences, Inc. | 5 | $86 |
| Abbott | 3 | $70 |
| Kyowa Kirin, Inc. | 3 | $59 |
| Tanabe Pharma America, Inc. | 3 | $57 |
| Jazz Pharmaceuticals Inc. | 2 | $52 |
| Amgen | 2 | $41 |
| Itamar Medical Inc | 1 | $40 |
| Bristol Myers Squibb | 2 | $40 |
| Catalyst Pharmaceuticals, Inc. | 2 | $33 |
| Amneal Pharmaceuticals LLC | 1 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| GE HealthCare | 1 | $25 |
| Johnson & Johnson | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 1 | $23 |
| EMD Serono, Inc. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Acadia Pharmaceuticals Inc | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYVGART HYTRULO$4,800
- VNS Therapy$969
- NURTEC ODT$243
- XCOPRI$125
- SOLIRIS$118
How this compares
$38,176 in reported general payments places this provider in the 90th percentile of 132 neurology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 36 | $375,073 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $216,930 |
| Austedo XrDeutetrabenazine | 24 | $135,116 |
| Nurtec OdtRimegepant Sulfate | 95 | $128,373 |
| XcopriCenobamate | 61 | $71,130 |
| Emgality PenGalcanezumab-Gnlm | 48 | $49,541 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 37 | $45,735 |
| QuliptaAtogepant | 22 | $37,138 |
| RytaryCarbidopa/Levodopa | 25 | $30,316 |
| GlatopaGlatiramer Acetate | 13 | $29,547 |
| BotoxOnabotulinumtoxina | 14 | $24,473 |
| UbrelvyUbrogepant | 20 | $22,231 |
| AptiomEslicarbazepine Acetate | 14 | $20,212 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 845 | $16,076 |
| FycompaPerampanel | 13 | $15,718 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $25 | $216,93013 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $197 | $135,11624 claims |
| PfizerNurtec Odt | $642 | $128,37395 claims |
| AbbVieQulipta, Botox, Ubrelvy | $502 | $83,84256 claims |
| SK Life Science, Inc.Xcopri | $271 | $71,13061 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $30 | $31,63959 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $23 | $20,21214 claims |
| Lilly USA, LLCReyvow | $101 | $10,13215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 132 neurology providers in Iowa.
Other neurology in West Burlington
- Anil DhunaWest Burlington$3K
- Aneesh NeekhraWest Burlington$1K
- Bruce HughesDes Moines$1.8M
- Michael JacobyDes Moines$243K
- Lynn RankinDes Moines$181K
- Winthrop RiskCedar Rapids$136K
- Wendy ZadehDes Moines$134K
- Paul BabikianDes Moines$107K
- Scott GeislerCedar Rapids$87K
- Douglas NathansonIowa City$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.